Off-the-shelf cell therapy takes on hard-to-treat blood cancers

NCT ID NCT03666000

Recruiting now Disease control Sponsor: Imugene Limited Source: ClinicalTrials.gov ↗

First seen Feb 02, 2026 · Last updated Apr 30, 2026 · Updated 12 times

Summary

This early-stage trial is testing a new treatment called Azer-cel for adults with certain blood cancers (non-Hodgkin lymphoma, B-cell acute lymphoblastic leukemia, and related conditions) that have returned or stopped responding to standard therapy. Azer-cel is a type of immune cell therapy made from donor cells, so it can be given "off the shelf" without needing to collect the patient's own cells. The study aims to find the safest dose and see if the treatment can shrink tumors or put the cancer into remission.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Banner MD Anderson Cancer Center
COMPLETED

Gilbert, Arizona, 85234, United States
Barbara Ann Karmanos Cancer Institute (Wayne State University)
COMPLETED

Detroit, Michigan, 48201, United States
Barwon Health - Andrew Love Cancer Centre
RECRUITING

Geelong, Victoria, 3320, Australia

Contact
Baylor University Medical Center
RECRUITING

Dallas, Texas, 75246, United States

Contact

Contact
City of Hope
COMPLETED

Duarte, California, 91010, United States
Columbia University Irving Medical Center/New York Presbyterian Hospital
RECRUITING

New York, New York, 10032, United States

Contact

Contact
Dana-Farber Cancer Institute
COMPLETED

Boston, Massachusetts, 02215, United States
Duke University
COMPLETED

Durham, North Carolina, 27708, United States
H. Lee Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States

Contact

Contact
Lifespan Cancer Institute at Rhode Island Hospital
RECRUITING

Providence, Rhode Island, 02903, United States

Contact

Contact
Liverpool Hospital
RECRUITING

Liverpool, New South Wales, 2170, Australia

Contact
MD Anderson
COMPLETED

Houston, Texas, 77030, United States
Medical College of Wisconsin
RECRUITING

Milwaukee, Wisconsin, 53226, United States

Contact

Contact
Northside Hospital Cancer Institute
RECRUITING

Atlanta, Georgia, 30342, United States

Contact

Contact
Ohio State University
COMPLETED

Columbus, Ohio, 43210, United States
Royal Adelaide Hospital
RECRUITING

Adelaide, South Australia, 5000, Australia

Contact
Royal Prince Alfred Hospital
RECRUITING

Camperdown, New South Wales, 2050, Australia

Contact
St Vincent's Hospital Melbourne
RECRUITING

Fitzroy, Victoria, 3065, Australia

Contact
Tufts Medical Center
RECRUITING

Boston, Massachusetts, 02111, United States

Contact

Contact
University of Maryland
RECRUITING

Baltimore, Maryland, 21201, United States

Contact

Contact
University of Minnesota
RECRUITING

Minneapolis, Minnesota, 55455, United States

Contact

Contact
Weill Cornell Medical College - NY Presbyterian Hospital
COMPLETED

New York, New York, 10021, United States
Winship Cancer Institute Emory University
RECRUITING

Atlanta, Georgia, 30322, United States

Contact

Contact

Conditions

Explore the condition pages connected to this study.

B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CHRONIC LYMPHOCYTIC LEUKEMIA NON-HODGKIN LYMPHOMA SMALL LYMPHOCYTIC LYMPHOMA